In today's episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b. So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health? Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped. In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here. Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Links: Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6 Montgomery-Asberg Depression Rating Scale (MADRS): https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale MAPS MDMA-PTSD Study: https://www.nytimes.com/2021/05/03/health/mdma-approval.html Comp 360 Open Label Study: https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html MindMed Psilocybin SSRI Study: https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #CompassPathways #psilocybin #depression

Analyzing the Quarter 3 financial results of atai Life Sciences (Nasdaq: ATAI), Compass Pathways (Nasdaq: CMPS), MindMed (Nasdaq: MNMD) and Cybin (NYSE: CYBN). It’s earning season! In this episode we compare and contrast the financials of the four biggest companies in the psychedelic medicines space, atai, Compass Pathways, MindMed and CYBIN. All four released their Q3 financials in the past week. All four are the biggest psychedelic stocks We also look at some of the highlights of the past quarter for each company, and do some rough back of the napkin math to determine when they will need to raise more capital. Atai Life Sciences (atai stock) is the best financed company, and had a very eventful quarter. They started clinical trials studying r-ketamine, ibogaine, a schizophrenia drug and more. Compass Pathways (CMPS stock), the next best financed psychedelics company, released the results of their long awaited Comp 360 phase 2b clinical trial, testing treating Treatment-Resistant Depression with psilocybin. They also announced a new trial using comp 360 to treat PTSD, hired the famous Hamilton Morris, and acquired an IP portfolio of novel medicines. MindMed (MNMD Stock) had a quieter quarter, though it was still impressive. Despite having over a hundred million dollars in the bank, since they are spending so much on their million projects, they will likely have to raise capital through dilution within a year. Their work with LSD, 18-MC Psilocybin and more continues in the background, but this quarter was all about hiring talent. Cybin (CYBN stock) is in a bigger cash crunch, only having enough capital for roughly a year. This means they will almost certainly be raising capital soon. Despite this, they had a great quarter and announced that their lead drug candidate CYB-003, a modified version of psilocybin, shows great promise in animal models. Links: Atai: https://www.atai.life/2021/11/05/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update/ Compass Pathways: https://compasspathways.com/financial-results-and-business-highlights-for-the-third-quarter-2021/ MindMed: https://www.prnewswire.com/news-releases/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cash-balance-of-145-9-usd-185-4-cad-to-execute-on-diverse-clinical-pipeline-301423844.html Cybin: https://www.businesswire.com/news/home/20211115005552/en/Cybin-Inc.-Reports-its-Second-Quarter-Financial-Results-and-Recent-Business-Highlights Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #ataiLifeSciences #MindMed #Cybin

Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”